Recursion Pharmaceuticals, Inc.

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
7.35 ^USD	+2.65%		-16.10%	-25.46%

Jul. 01	Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) dropped from Russell 2500 Value Index	CI
Jul. 01	Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 3000E Growth Index	CI

Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) dropped from Russell 3000E Value Index

July 30, 2024

Latest news about Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) dropped from Russell 2500 Value Index	Jun. 30	CI
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 3000E Growth Index	Jun. 30	CI
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 3000 Growth Index	Jun. 30	CI
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) dropped from Russell 2000 Value Index	Jun. 30	CI
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 2000 Growth Index	Jun. 30	CI
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 2500 Growth Index	Jun. 30	CI
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) dropped from Russell 3000E Value Index	Jun. 30	CI
Sector Update: Health Care Stocks Mixed Premarket Thursday	Jun. 27	MT
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	Jun. 27	MT
Recursion Pharmaceuticals Prices $200 Million Stock Offering	Jun. 27	MT
Recursion Pharmaceuticals Plans $200 Million Public Offering	Jun. 26	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $278,880, According to a Recent SEC Filing	Jun. 17	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing	Jun. 07	MT
Recursion Names HilleVax CEO Robert Hershberg as New Board Chair	May. 24	MT
Recursion Pharmaceuticals, Inc. Announces Chair of the Board Changes	May. 24	CI
Recursion Pharmaceuticals Says BioHive-2 AI Supercomputer Completed	May. 13	MT
Recursion Announces Completion of NVIDIA-Powered BioHive-2	May. 13	CI
Recursion Pharmaceuticals Q1 Loss Widens, Revenue Rises	May. 09	MT
Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q1 Revenue $13.8M, vs. Street Est of $12.7M	May. 09	MT
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	Apr. 18	MT
Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	Apr. 16	MT
Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer	Apr. 16	CI
Recursion Pharmaceuticals Insider Sold Shares Worth $537,190, According to a Recent SEC Filing	Mar. 15	MT

Chart Recursion Pharmaceuticals, Inc.

Duration

Period

More charts

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Recursion Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.35 USD

Average target price

12.83 USD

Spread / Average Target

+74.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RECURSION PHARMACEUTICALS, INC.	-25.46%	1.97B
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	121B
REGENERON PHARMACEUTICALS, INC.	+16.60%	110B
ARGENX SE	+18.11%	25.93B
BIONTECH SE	-24.33%	19.27B
GENMAB A/S	-19.26%	16.01B
BEIGENE, LTD.	-17.95%	15.66B
WUXI APPTEC CO., LTD.	-46.81%	14.89B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.47B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.91B

Bio Therapeutic Drugs